Get the Stockscreener App
1.90
3.81%
-0.07
Iovance Biotherapeutics Inc stock is traded at $1.90, with a volume of 44.01M.
It is down -3.81% in the last 24 hours and down -19.02% over the past month.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
See More
Previous Close:
$1.97
Open:
$2.155
24h Volume:
44.01M
Relative Volume:
3.48
Market Cap:
$683.90M
Revenue:
$241.53M
Net Income/Loss:
$-389.92M
P/E Ratio:
-1.5447
EPS:
-1.23
Net Cash Flow:
$-323.54M
1W Performance:
-17.97%
1M Performance:
-19.02%
6M Performance:
-45.86%
1Y Performance:
-83.07%
1-Day Range:
$1.855
$2.20
1-Week Range:
$1.855
$2.35
52-Week Range:
$1.6385
$12.51
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Name
Iovance Biotherapeutics Inc
Sector
Industry
Phone
(650) 260-7120
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
1.89 | 712.85M | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.52 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.42 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.79 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.21 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.05 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Downgrade | Goldman | Neutral → Sell |
| May-16-25 | Downgrade | UBS | Buy → Neutral |
| May-12-25 | Downgrade | Truist | Buy → Hold |
| May-09-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Jul-29-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Sep-18-23 | Reiterated | Barclays | Overweight |
| May-30-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Aug-18-22 | Resumed | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Stifel | Hold → Buy |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Jun-10-21 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| May-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-21 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| May-19-21 | Downgrade | Stifel | Buy → Hold |
| May-03-21 | Initiated | Truist | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-15-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-06-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-26-20 | Reiterated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Apr-29-19 | Initiated | Piper Jaffray | Overweight |
| Feb-28-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-07-19 | Initiated | Robert W. Baird | Outperform |
| Dec-31-18 | Resumed | B. Riley FBR | Buy |
| Jul-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Apr-10-18 | Upgrade | B. Riley FBR, Inc. | Neutral → Buy |
| Mar-13-18 | Reiterated | B. Riley FBR, Inc. | Neutral |
| Feb-23-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Jan-25-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-01-17 | Reiterated | B. Riley FBR, Inc. | Buy |
View All
Iovance Biotherapeutics Inc Stock (IOVA) Latest News
Why Iovance Biotherapeutics Inc. stock is favored by top institutions - newser.com
Iovance Biotherapeutics Stock Rises Premarket on Positive Trial Data for Cancer Drug - MarketScreener
Why Iovance Biotherapeutics Inc. stock appeals to analystsQuarterly Market Summary & Daily Stock Trend Watchlist - newser.com
Why Iovance Biotherapeutics Inc. stock attracts global investors2025 Market Sentiment & Community Driven Trade Alerts - newser.com
Iovance (IOVA) Reports Promising Interim Results from Phase 2 Tr - GuruFocus
Automated trading signals detected on Iovance Biotherapeutics Inc.Weekly Trading Summary & Fast Gaining Stock Reports - newser.com
Iovance (NASDAQ: IOVA) lifileucel posts 26% ORR in NSCLC; mDOR not reached at 25.4 months - Stock Titan
How big funds are accumulating Iovance Biotherapeutics Inc. (2LB) stockOil Prices & Fast Entry and Exit Trade Plans - newser.com
Is Iovance Biotherapeutics Inc. stock a good choice for value investorsJuly 2025 Summary & Risk Managed Investment Signals - newser.com
Published on: 2025-11-03 05:20:39 - newser.com
Quantitative breakdown of Iovance Biotherapeutics Inc. recent moveBreakout Watch & Real-Time Chart Pattern Alerts - newser.com
What earnings margins imply for Iovance Biotherapeutics Inc. (2LB) stockWeekly Gains Report & Consistent Profit Alerts - newser.com
Published on: 2025-11-03 03:17:06 - newser.com
Is it time to cut losses on Iovance Biotherapeutics Inc.2025 Breakouts & Breakdowns & Low Risk High Win Rate Picks - newser.com
Will Iovance Biotherapeutics Inc. stock beat EPS estimatesMarket Activity Summary & Free Daily Entry Point Trade Alerts - newser.com
Does Iovance Biotherapeutics Inc. stock trade at a discount to peersEarnings Miss & Low Drawdown Momentum Trade Ideas - newser.com
Will Iovance Biotherapeutics Inc. stock gain from lower inflationWeekly Profit Summary & Risk Managed Investment Entry Signals - newser.com
What insider trading reveals about Iovance Biotherapeutics Inc. stockEarnings Growth Summary & Weekly High Conviction Ideas - newser.com
Iovance Biotherapeutics Stock Hits Day Low of $2 Amid Price Pressure - Markets Mojo
How Iovance Biotherapeutics Inc. stock trades during market volatilityJuly 2025 Highlights & Reliable Entry Point Trade Alerts - newser.com
How supply shortages influence Iovance Biotherapeutics Inc. (2LB) stockNew Guidance & Free Expert Approved Momentum Trade Ideas - newser.com
HC Wainwright Issues Negative Forecast for IOVA Earnings - MarketBeat
Published on: 2025-11-01 04:05:22 - newser.com
Can Iovance Biotherapeutics Inc. stock deliver strong Q4 earnings2025 Geopolitical Influence & High Accuracy Investment Signals - newser.com
Using portfolio simulators with Iovance Biotherapeutics Inc. includedWeekly Investment Recap & Advanced Technical Signal Analysis - newser.com
What Wall Street predicts for Iovance Biotherapeutics Inc. stock price2025 Valuation Update & Stepwise Entry and Exit Trade Signals - newser.com
Is Iovance Biotherapeutics Inc. stock poised for growth2025 Breakouts & Breakdowns & Weekly Chart Analysis and Trade Guides - newser.com
Iovance Biotherapeutics (IOVA) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Using RSI to spot recovery in Iovance Biotherapeutics Inc.Earnings Trend Report & Growth Focused Stock Reports - newser.com
Can trapped investors hope for a rebound in Iovance Biotherapeutics Inc.2025 Momentum Check & Daily Stock Trend Reports - newser.com
Will Iovance Biotherapeutics Inc. stock see PE expansionJuly 2025 Analyst Calls & AI Enhanced Trading Signals - newser.com
Published on: 2025-10-31 03:11:42 - newser.com
Published on: 2025-10-31 02:59:28 - newser.com
Iovance Biotherapeutics Inc Stock (IOVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):